查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1812374

放射性药物市场

Radiopharmaceuticals Market
出版日期: | 出版商: Transparency Market Research | 英文 209 Pages | 商品交期: 2-10个工作天内

价格

放射性药物市场-报告范围

TMR 的全球放射性药物市场报告研究了过去和当前的成长趋势和机会，以获得 2025 年至 2035 年预测期内市场指标的宝贵见解。该报告提供了 2025 年至 2035 年期间全球放射性药物市场的收入，以 2025 年为基准年，2035 年为预测年。报告中还提供了 2025 年至 2035 年期间全球放射性药物市场的年复合成长率(CAGR %)。

本报告经过广泛的研究后编写。主要研究工作量较大，分析师访问了关键意见领袖、产业领袖和舆论领袖。次要研究则参考了主要厂商的产品资料、年度报告、新闻稿和相关文件，以了解两轮车导航显示器市场。

市场概况
2024年的市场价值 66亿美元
2035年的市场价值 146亿美元
复合年增长率 7.6%

本报告深入探讨了全球两轮车导航显示器市场的竞争格局。该报告确定了全球放射性药物市场的主要参与者，并根据其各项属性对每位参与者进行了分析。本报告对全球放射性药物市场参与者的属性进行了概述，包括公司概况、财务状况、近期发展和 SWOT 分析。

全球放射性药物市场报告解答的关键问题：

  • 预测期内，所有地区的血液分离术销售额/收入为何？
  • 全球两轮车导航显示器市场有哪些机会？
  • 市场的主要驱动因素、限制因素、机会和威胁是什么？
  • 在预测期内，哪个区域市场将以最快的复合年增长率扩张？
  • 预计哪个领域将在 2035 年创造全球最高收入？
  • 预测期内，哪个细分市场预计以最高复合年增长率扩张？
  • 在全球市场中经营的不同公司的市场地位如何？

放射性药物市场-研究目标与研究方法

这份关于全球放射性药物市场的综合报告首先概述了研究范围和目标。报告详细阐述了本研究的目标、市场中的主要供应商和分销商，以及产品审批的监管情况。

为了方便阅读，本报告采用章节式编排，每个章节又细分为多个小节。报告包含详尽的图表，并适当穿插。各关键细分市场的实际值和预测值以图形方式呈现，视觉上引人入胜。此外，报告也便于读者比较过去和预测期末各关键细分市场的市占率。

本报告从产品、最终用户和地区角度分析了全球放射性药物市场。该报告对每个标准下的关键细分市场进行了深入研究，并提供了2035年底每个细分市场的市场份额。这些宝贵的见解使市场利益相关者能够在全球两轮车导航显示器市场投资时做出明智的商业决策。

目录

第一章：前言

第二章：假设与研究方法

第三章：执行摘要：全球市场

第四章：市场概况

  • 介绍
  • 概述
  • 市场动态
  • 2020年至2035年全球放射性药物市场分析与预测

第五章：关键见解

  • FDA核准的放射性药物产品
  • 重大疾病流行病学
  • 主要国家/地区报销情况
  • 定价分析
  • 管道分析
  • 技术进步与发展
  • 放射治疗领域先锋标靶治疗的见解
  • 各国/地区监管情况
  • 重要产业事件（产品发布、重要併购等）
  • 放射治疗中心数量：主要国家

第六章：全球市场分析与预测：依放射性同位素

  • 介绍与定义
  • 主要发现/进展
  • 市值预测：依放射性同位素，2020 年至 2035 年
    • 诊断
      • 氟-18（F-18）
        • 氟脱氧葡萄糖（FDG）
        • 氟化钠
        • 氟西可维因
        • 氟倍他吡尔
        • 氟倍他班
        • 其他的
      • 镓-68（Ga-68）
        • 多塔塔特
        • 多塔托克
        • PSMA-11
      • 锝-99m（Tc-99）
      • 碘-123（I-123）
      • 其他的
    • 治疗
      • 碘-131（I-131）
      • 钇-90（Y-90）
      • 镥-177（Lu-177）
        • Lu-PSMA-617
        • 露-DOTA-TATE
      • 其他的
  • 市场吸引力分析：放射性同位素

第七章：全球市场分析与预测：按应用

  • 介绍与定义
  • 主要发现/进展
  • 市场价值预测：按应用，2020 年至 2035 年
    • 肿瘤学
      • 摄护腺癌
      • 乳癌
      • 神经内分泌肿瘤
      • 甲状腺癌
      • 大肠直肠癌
      • 肝癌
      • 其他的
    • 神经病学
      • 阿兹海默症
      • 帕金森氏症
      • 其他的
    • 心臟病学
    • 其他的
  • 市场吸引力分析：按应用

第八章：全球市场分析与预测：按最终用户

  • 介绍与定义
  • 主要发现/进展
  • 市场价值预测：按最终用户，2020 年至 2035 年
    • 医院
    • 诊断和影像中心
    • 其他的
  • 市场吸引力分析：按最终用户

第九章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2020年至2035年
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第十章：北美市场分析与预测

第 11 章：欧洲市场分析与预测

第 12 章：亚太市场分析与预测

第十三章：拉丁美洲市场分析与预测

第 14 章：中东和非洲市场分析与预测

第 15 章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：按公司（2024年）
  • 公司简介
    • Advanced Accelerator Applications
    • Bayer AG
    • Eli Lilly and Company
    • GE Healthcare
    • ITM Isotopen Technologien Munchen AG
    • Jubilant Pharma Limited
    • Lantheus Holdings, Inc.
    • Nihon Medi-Physics
    • Siemens Healthineers AG
    • Telix Pharmaceuticals
Product Code: TMRGL213

Radiopharmaceuticals Market- Scope of Report

TMR's report on the global Radiopharmaceuticals Marketstudies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Radiopharmaceuticals Marketfor the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Radiopharmaceuticals Marketfrom 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Radiopharmaceuticals Market .

Market Snapshot
Market Value in 2024US$ 6.6 Bn
Market Value in 2035US$ 14.6 Bn
CAGR7.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Radiopharmaceuticals Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Radiopharmaceuticals Market . These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Radiopharmaceuticals Market .

The report delves into the competitive landscape of the global Radiopharmaceuticals Market . Key players operating in the global Radiopharmaceuticals Markethave been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Radiopharmaceuticals Marketprofiled in this report.

Key Questions Answered in Global Radiopharmaceuticals MarketReport:

  • What are the opportunities in the global Radiopharmaceuticals Market ?
  • What are the major drivers, restraints, opportunities, and threats in the Market ?
  • Which regional Market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the Market positions of different companies operating in the global Market ?

Radiopharmaceuticals Market- Research Objectives and Research Approach

The comprehensive report on the global Radiopharmaceuticals Marketbegins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Radiopharmaceuticals Marketin terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Radiopharmaceuticals Market .

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Radiopharmaceuticals Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Radiopharmaceuticals Market Analysis and Forecast, 2020 to 2035
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. FDA Approved Radiopharmaceuticals Products
  • 5.2. Epidemiology of Major Diseases
  • 5.3. Reimbursement Scenario by key Countries/Regions
  • 5.4. Pricing Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Technological Advancements & Development
  • 5.7. Insights on Pioneering Targeted in Radiotherapy
  • 5.8. Regulatory Scenario by Country/Regions
  • 5.9. Key Industry Events (Product Launch, Key Mergers and Acquisitions, etc.)
  • 5.10. Number of Radiotherapy Centers: Major Country

6. Global Radiopharmaceuticals Market Analysis and Forecast, by Radioisotopes

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Radioisotopes, 2020 to 2035
    • 6.3.1. Diagnostics
      • 6.3.1.1. Fluorine-18 (F-18)
        • 6.3.1.1.1. Fludeoxyglucose (FDG)
        • 6.3.1.1.2. Sodium Fluoride
        • 6.3.1.1.3. Flucicovine
        • 6.3.1.1.4. Florbetapir
        • 6.3.1.1.5. Florbetaben
        • 6.3.1.1.6. Others
      • 6.3.1.2. Gallium-68 (Ga-68)
        • 6.3.1.2.1. Dotatate
        • 6.3.1.2.2. Dotatoc
        • 6.3.1.2.3. PSMA-11
      • 6.3.1.3. Technetium-99m (Tc-99)
      • 6.3.1.4. Iodine-123 (I-123)
      • 6.3.1.5. Others
    • 6.3.2. Therapy
      • 6.3.2.1. Iodine-131 (I-131)
      • 6.3.2.2. Yttrium-90 (Y-90)
      • 6.3.2.3. Lutetium-177 (Lu-177)
        • 6.3.2.3.1. Lu-PSMA-617
        • 6.3.2.3.2. Lu-DOTA-TATE
      • 6.3.2.4. Others
  • 6.4. Market Attractiveness Analysis, by Radioisotopes

7. Global Radiopharmaceuticals Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Application, 2020 to 2035
    • 7.3.1. Oncology
      • 7.3.1.1. Prostate Cancer
      • 7.3.1.2. Breast Cancer
      • 7.3.1.3. Neuroendocrine Tumors
      • 7.3.1.4. Thyroid Cancer
      • 7.3.1.5. Colorectal Cancer
      • 7.3.1.6. Liver Cancer
      • 7.3.1.7. Others
    • 7.3.2. Neurology
      • 7.3.2.1. Alzheimer's Disease
      • 7.3.2.2. Parkinson's Disease
      • 7.3.2.3. Others
    • 7.3.3. Cardiology
    • 7.3.4. Others
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Radiopharmaceuticals Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by End-user, 2020 to 2035
    • 8.3.1. Hospitals
    • 8.3.2. Diagnostics and Imaging Centers
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Radiopharmaceuticals Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020 to 2035
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Radiopharmaceuticals Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
    • 10.2.1. Diagnostics
      • 10.2.1.1. Fluorine-18 (F-18)
        • 10.2.1.1.1. Fludeoxyglucose (FDG)
        • 10.2.1.1.2. Sodium Fluoride
        • 10.2.1.1.3. Flucicovine
        • 10.2.1.1.4. Florbetapir
        • 10.2.1.1.5. Florbetaben
        • 10.2.1.1.6. Others
      • 10.2.1.2. Gallium-68 (Ga-68)
        • 10.2.1.2.1. Dotatate
        • 10.2.1.2.2. Dotatoc
        • 10.2.1.2.3. PSMA-11
      • 10.2.1.3. Technetium-99m (Tc-99)
      • 10.2.1.4. Iodine-123 (I-123)
      • 10.2.1.5. Others
    • 10.2.2. Therapy
      • 10.2.2.1. Iodine-131 (I-131)
      • 10.2.2.2. Yttrium-90 (Y-90)
      • 10.2.2.3. Lutetium-177 (Lu-177)
        • 10.2.2.3.1. Lu-PSMA-617
        • 10.2.2.3.2. Lu-DOTA-TATE
      • 10.2.2.4. Others
  • 10.3. Market Value Forecast, by Application, 2020 to 2035
    • 10.3.1. Oncology
      • 10.3.1.1. Prostate Cancer
      • 10.3.1.2. Breast Cancer
      • 10.3.1.3. Neuroendocrine Tumors
      • 10.3.1.4. Thyroid Cancer
      • 10.3.1.5. Colorectal Cancer
      • 10.3.1.6. Liver Cancer
      • 10.3.1.7. Others
    • 10.3.2. Neurology
      • 10.3.2.1. Alzheimer's Disease
      • 10.3.2.2. Parkinson's Disease
      • 10.3.2.3. Others
    • 10.3.3. Cardiology
    • 10.3.4. Others
  • 10.4. Market Value Forecast, by End-user, 2020 to 2035
    • 10.4.1. Hospitals
    • 10.4.2. Diagnostics and Imaging Centers
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country, 2020 to 2035
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Radioisotopes
    • 10.6.2. By Application
    • 10.6.3. By End-user
    • 10.6.4. By Country

11. Europe Radiopharmaceuticals Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
    • 11.2.1. Diagnostics
      • 11.2.1.1. Fluorine-18 (F-18)
        • 11.2.1.1.1. Fludeoxyglucose (FDG)
        • 11.2.1.1.2. Sodium Fluoride
        • 11.2.1.1.3. Flucicovine
        • 11.2.1.1.4. Florbetapir
        • 11.2.1.1.5. Florbetaben
        • 11.2.1.1.6. Others
      • 11.2.1.2. Gallium-68 (Ga-68)
        • 11.2.1.2.1. Dotatate
        • 11.2.1.2.2. Dotatoc
        • 11.2.1.2.3. PSMA-11
      • 11.2.1.3. Technetium-99m (Tc-99)
      • 11.2.1.4. Iodine-123 (I-123)
      • 11.2.1.5. Others
    • 11.2.2. Therapy
      • 11.2.2.1. Iodine-131 (I-131)
      • 11.2.2.2. Yttrium-90 (Y-90)
      • 11.2.2.3. Lutetium-177 (Lu-177)
        • 11.2.2.3.1. Lu-PSMA-617
        • 11.2.2.3.2. Lu-DOTA-TATE
      • 11.2.2.4. Others
  • 11.3. Market Value Forecast, by Application, 2020 to 2035
    • 11.3.1. Oncology
      • 11.3.1.1. Prostate Cancer
      • 11.3.1.2. Breast Cancer
      • 11.3.1.3. Neuroendocrine Tumors
      • 11.3.1.4. Thyroid Cancer
      • 11.3.1.5. Colorectal Cancer
      • 11.3.1.6. Liver Cancer
      • 11.3.1.7. Others
    • 11.3.2. Neurology
      • 11.3.2.1. Alzheimer's Disease
      • 11.3.2.2. Parkinson's Disease
      • 11.3.2.3. Others
    • 11.3.3. Cardiology
    • 11.3.4. Others
  • 11.4. Market Value Forecast, by End-user, 2020 to 2035
    • 11.4.1. Hospitals
    • 11.4.2. Diagnostics and Imaging Centers
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
    • 11.5.1. Germany
    • 11.5.2. UK
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Switzerland
    • 11.5.7. The Netherlands
    • 11.5.8. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Radioisotopes
    • 11.6.2. By Application
    • 11.6.3. By End-user
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Radiopharmaceuticals Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
    • 12.2.1. Diagnostics
      • 12.2.1.1. Fluorine-18 (F-18)
        • 12.2.1.1.1. Fludeoxyglucose (FDG)
        • 12.2.1.1.2. Sodium Fluoride
        • 12.2.1.1.3. Flucicovine
        • 12.2.1.1.4. Florbetapir
        • 12.2.1.1.5. Florbetaben
        • 12.2.1.1.6. Others
      • 12.2.1.2. Gallium-68 (Ga-68)
        • 12.2.1.2.1. Dotatate
        • 12.2.1.2.2. Dotatoc
        • 12.2.1.2.3. PSMA-11
      • 12.2.1.3. Technetium-99m (Tc-99)
      • 12.2.1.4. Iodine-123 (I-123)
      • 12.2.1.5. Others
    • 12.2.2. Therapy
      • 12.2.2.1. Iodine-131 (I-131)
      • 12.2.2.2. Yttrium-90 (Y-90)
      • 12.2.2.3. Lutetium-177 (Lu-177)
        • 12.2.2.3.1. Lu-PSMA-617
        • 12.2.2.3.2. Lu-DOTA-TATE
      • 12.2.2.4. Others
  • 12.3. Market Value Forecast, by Application, 2020 to 2035
    • 12.3.1. Oncology
      • 12.3.1.1. Prostate Cancer
      • 12.3.1.2. Breast Cancer
      • 12.3.1.3. Neuroendocrine Tumors
      • 12.3.1.4. Thyroid Cancer
      • 12.3.1.5. Colorectal Cancer
      • 12.3.1.6. Liver Cancer
      • 12.3.1.7. Others
    • 12.3.2. Neurology
      • 12.3.2.1. Alzheimer's Disease
      • 12.3.2.2. Parkinson's Disease
      • 12.3.2.3. Others
    • 12.3.3. Cardiology
    • 12.3.4. Others
  • 12.4. Market Value Forecast, by End-user, 2020 to 2035
    • 12.4.1. Hospitals
    • 12.4.2. Diagnostics and Imaging Centers
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. South Korea
    • 12.5.5. Australia & Newzealend
    • 12.5.6. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Radioisotopes
    • 12.6.2. By Application
    • 12.6.3. By End-user
    • 12.6.4. By Country/Sub-region

13. Latin America Radiopharmaceuticals Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
    • 13.2.1. Diagnostics
      • 13.2.1.1. Fluorine-18 (F-18)
        • 13.2.1.1.1. Fludeoxyglucose (FDG)
        • 13.2.1.1.2. Sodium Fluoride
        • 13.2.1.1.3. Flucicovine
        • 13.2.1.1.4. Florbetapir
        • 13.2.1.1.5. Florbetaben
        • 13.2.1.1.6. Others
      • 13.2.1.2. Gallium-68 (Ga-68)
        • 13.2.1.2.1. Dotatate
        • 13.2.1.2.2. Dotatoc
        • 13.2.1.2.3. PSMA-11
      • 13.2.1.3. Technetium-99m (Tc-99)
      • 13.2.1.4. Iodine-123 (I-123)
      • 13.2.1.5. Others
    • 13.2.2. Therapy
      • 13.2.2.1. Iodine-131 (I-131)
      • 13.2.2.2. Yttrium-90 (Y-90)
      • 13.2.2.3. Lutetium-177 (Lu-177)
        • 13.2.2.3.1. Lu-PSMA-617
        • 13.2.2.3.2. Lu-DOTA-TATE
      • 13.2.2.4. Others
  • 13.3. Market Value Forecast, by Application, 2020 to 2035
    • 13.3.1. Oncology
      • 13.3.1.1. Prostate Cancer
      • 13.3.1.2. Breast Cancer
      • 13.3.1.3. Neuroendocrine Tumors
      • 13.3.1.4. Thyroid Cancer
      • 13.3.1.5. Colorectal Cancer
      • 13.3.1.6. Liver Cancer
      • 13.3.1.7. Others
    • 13.3.2. Neurology
      • 13.3.2.1. Alzheimer's Disease
      • 13.3.2.2. Parkinson's Disease
      • 13.3.2.3. Others
    • 13.3.3. Cardiology
    • 13.3.4. Others
  • 13.4. Market Value Forecast, by End-user, 2020 to 2035
    • 13.4.1. Hospitals
    • 13.4.2. Diagnostics and Imaging Centers
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Argentina
    • 13.5.4. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Radioisotopes
    • 13.6.2. By Application
    • 13.6.3. By End-user
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Radiopharmaceuticals Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Radioisotopes, 2020 to 2035
    • 14.2.1. Diagnostics
      • 14.2.1.1. Fluorine-18 (F-18)
        • 14.2.1.1.1. Fludeoxyglucose (FDG)
        • 14.2.1.1.2. Sodium Fluoride
        • 14.2.1.1.3. Flucicovine
        • 14.2.1.1.4. Florbetapir
        • 14.2.1.1.5. Florbetaben
        • 14.2.1.1.6. Others
      • 14.2.1.2. Gallium-68 (Ga-68)
        • 14.2.1.2.1. Dotatate
        • 14.2.1.2.2. Dotatoc
        • 14.2.1.2.3. PSMA-11
      • 14.2.1.3. Technetium-99m (Tc-99)
      • 14.2.1.4. Iodine-123 (I-123)
      • 14.2.1.5. Others
    • 14.2.2. Therapy
      • 14.2.2.1. Iodine-131 (I-131)
      • 14.2.2.2. Yttrium-90 (Y-90)
      • 14.2.2.3. Lutetium-177 (Lu-177)
        • 14.2.2.3.1. Lu-PSMA-617
        • 14.2.2.3.2. Lu-DOTA-TATE
      • 14.2.2.4. Others
  • 14.3. Market Value Forecast, by Application, 2020 to 2035
    • 14.3.1. Oncology
      • 14.3.1.1. Prostate Cancer
      • 14.3.1.2. Breast Cancer
      • 14.3.1.3. Neuroendocrine Tumors
      • 14.3.1.4. Thyroid Cancer
      • 14.3.1.5. Colorectal Cancer
      • 14.3.1.6. Liver Cancer
      • 14.3.1.7. Others
    • 14.3.2. Neurology
      • 14.3.2.1. Alzheimer's Disease
      • 14.3.2.2. Parkinson's Disease
      • 14.3.2.3. Others
    • 14.3.3. Cardiology
    • 14.3.4. Others
  • 14.4. Market Value Forecast, by End-user, 2020 to 2035
    • 14.4.1. Hospitals
    • 14.4.2. Diagnostics and Imaging Centers
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Radioisotopes
    • 14.6.2. By Application
    • 14.6.3. By End-user
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2024)
  • 15.3. Company Profiles
    • 15.3.1. Advanced Accelerator Applications
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Bayer AG
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. Eli Lilly and Company
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. GE Healthcare
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. ITM Isotopen Technologien Munchen AG
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. Jubilant Pharma Limited
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Developments
    • 15.3.7. Lantheus Holdings, Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. Nihon Medi-Physics
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. Siemens Healthineers AG
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments
    • 15.3.10. Telix Pharmaceuticals
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Financial Overview
      • 15.3.10.3. Product Portfolio
      • 15.3.10.4. Business Strategies
      • 15.3.10.5. Recent Developments

List of Tables

  • Table 01: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
  • Table 02: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
  • Table 03: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
  • Table 04: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
  • Table 05: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
  • Table 06: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
  • Table 07: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
  • Table 08: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
  • Table 09: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
  • Table 10: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
  • Table 11: Global Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Region, 2020 to 2035
  • Table 12: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country, 2020 to 2035
  • Table 13: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
  • Table 14: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
  • Table 15: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
  • Table 16: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
  • Table 17: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
  • Table 18: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
  • Table 19: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
  • Table 20: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
  • Table 21: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
  • Table 22: North America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
  • Table 23: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
  • Table 24: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
  • Table 25: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
  • Table 26: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
  • Table 27: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
  • Table 28: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
  • Table 29: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
  • Table 30: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
  • Table 31: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
  • Table 32: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
  • Table 33: Europe Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
  • Table 34: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
  • Table 35: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
  • Table 36: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
  • Table 37: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
  • Table 38: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
  • Table 39: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
  • Table 40: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
  • Table 41: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
  • Table 42: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
  • Table 43: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
  • Table 44: Asia Pacific Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
  • Table 45: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
  • Table 46: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
  • Table 47: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
  • Table 48: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
  • Table 49: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
  • Table 50: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
  • Table 51: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
  • Table 52: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
  • Table 53: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
  • Table 54: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
  • Table 55: Latin America Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035
  • Table 56: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, by Country / Sub-region, 2020 to 2035
  • Table 57: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Radioisotopes, 2020 to 2035
  • Table 58: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Diagnostics, 2020 to 2035
  • Table 59: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Fluorine-18 (F-18), 2020 to 2035
  • Table 60: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Gallium-68 (Ga-68), 2020 to 2035
  • Table 61: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Therapy, 2020 to 2035
  • Table 62: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Lutetium-177 (Lu-177), 2020 to 2035
  • Table 63: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Application, 2020 to 2035
  • Table 64: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Oncology, 2020 to 2035
  • Table 65: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By Neurology, 2020 to 2035
  • Table 66: Middle East & Africa Radiopharmaceuticals Market Value (US$ Bn) Forecast, By End-user, 2020 to 2035

List of Figures

  • Figure 01: Global Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
  • Figure 02: Global Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
  • Figure 03: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Diagnostics, 2020 to 2035
  • Figure 04: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Therapy, 2020 to 2035
  • Figure 05: Global Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 06: Global Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 07: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Oncology, 2020 to 2035
  • Figure 08: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Neurology, 2020 to 2035
  • Figure 09: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Cardiology, 2020 to 2035
  • Figure 10: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Others, 2020 to 2035
  • Figure 11: Global Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 12: Global Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 13: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Hospitals, 2020 to 2035
  • Figure 14: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Diagnostics and Imaging Centers, 2020 to 2035
  • Figure 15: Global Radiopharmaceuticals Market Revenue (US$ Bn), by Others, 2020 to 2035
  • Figure 16: Global Radiopharmaceuticals Market Value Share Analysis, By Region, 2024 and 2035
  • Figure 17: Global Radiopharmaceuticals Market Attractiveness Analysis, By Region, 2025 to 2035
  • Figure 18: North America - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
  • Figure 19: North America - Radiopharmaceuticals Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 20: North America - Radiopharmaceuticals Market Attractiveness Analysis, by Country, 2025 to 2035
  • Figure 21: North America - Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
  • Figure 22: North America - Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
  • Figure 23: North America - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 24: North America - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 25: North America - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 26: North America - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 27: Europe - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
  • Figure 28: Europe - Radiopharmaceuticals Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 29: Europe - Radiopharmaceuticals Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
  • Figure 30: Europe Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
  • Figure 31: Europe Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
  • Figure 32: Europe - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 33: Europe - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 34: Europe - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 35: Europe - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 36: Asia Pacific - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
  • Figure 37: Asia Pacific - Radiopharmaceuticals Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 38: Asia Pacific - Radiopharmaceuticals Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
  • Figure 39: Asia Pacific - Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
  • Figure 40: Asia Pacific - Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
  • Figure 41: Asia Pacific - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 42: Asia Pacific - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 43: Asia Pacific - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 44: Asia Pacific - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 45: Latin America - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
  • Figure 46: Latin America - Radiopharmaceuticals Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 47: Latin America - Radiopharmaceuticals Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
  • Figure 48: Latin America - Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
  • Figure 49: Latin America - Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
  • Figure 50: Latin America - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 51: Latin America - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 52: Latin America - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 53: Latin America - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 54: Middle East & Africa - Radiopharmaceuticals Market Value (US$ Bn) Forecast, 2020 to 2035
  • Figure 55: Middle East & Africa - Radiopharmaceuticals Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 56: Middle East & Africa - Radiopharmaceuticals Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
  • Figure 57: Middle East & Africa - Radiopharmaceuticals Market Value Share Analysis, By Radioisotopes, 2024 and 2035
  • Figure 58: Middle East & Africa - Radiopharmaceuticals Market Attractiveness Analysis, By Radioisotopes, 2025 to 2035
  • Figure 59: Middle East & Africa - Radiopharmaceuticals Market Value Share Analysis, By Application, 2024 and 2035
  • Figure 60: Middle East & Africa - Radiopharmaceuticals Market Attractiveness Analysis, By Application, 2025 to 2035
  • Figure 61: Middle East & Africa - Radiopharmaceuticals Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 62: Middle East & Africa - Radiopharmaceuticals Market Attractiveness Analysis, By End-user, 2025 to 2035